docetaxel + leuprolide acetate

Combination of **docetaxel**, a taxane-class antineoplastic agent that stabilizes microtubules and inhibits their depolymerization, thereby blocking cell division and inducing apoptosis, and **leuprolide acetate**, a gonadotropin-releasing hormone (GnRH) receptor agonist that initially increases, then profoundly suppresses, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced circulating testosterone and estrogen. This combination is investigational for use as adjuvant or deferred therapy following radical prostatectomy in high-risk prostate cancer patients, aiming to suppress androgen-driven tumor progression by synergistically inhibiting cell proliferation and hormone stimulation[1][3][7].